All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

Wenxiu Yao, Liyang Wang, H. Z. Huang, Xin Li, Pinjia Wang, Kun Mi, Jia Cheng, Huifen Liu, Cuirong Gu, Lingxiao Huang, Jianming Huang

Abstract

Abstract Background: The enrichment of cancer stem cell-like cells (CSCs) has been considered to be responsible for tumor progression after an initial response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung adenocarcinoma (NSCLC/ADC). All-trans retinoic acid (ATRA) has been shown to potentiate cancer chemotherapy due to its ability to induce signals for CSC differentiation. We therefore investigated whether ATRA could improve the response of NSCLC/ADC cells to TKI gefitinib. Methods: Treatment of NSCLC/ADC A549 and H1650 cells with gefitinib enriched the gefitinib surviving cells (GSCs). The expression of ALDH1A1 and CD44 and the IC50 values for gefitinib were determined by flow cytometry (FCM) and crystal violet assay in GSCs and ATRA-treated GSCs, respectively. Results: GSCs showed higher expression of ALDH1A1 and CD44 and IC50 values for gefitinib than their respective parental cells, suggesting that gefitinib can lead to propagation of CSC-enriched gefitinib-resistant cells. Treatment with ATRA was found to significantly reduce the increased expression of ALDH1A1 and CD44 and the IC50 values for gefitinib in A549GSC and H1650GSC cells. Conclusion: Our findings suggest that combination treatment with ATRA prevents gefitinib-induced enrichment of ALDH1A1bright/CD44high CSCs and enhances gefitinib-induced growth inhibition of NSCLC/ADC cells. Key words: All-trans retinoic acid, ALDH1A1, CD44, EGFR tyrosine kinase inhibitors, non-small cell lung adenocarcinoma
BibTeX
@inproceedings{yao2020all,
  author = {Wenxiu Yao and Liyang Wang and H. Z. Huang and Xin Li and Pinjia Wang and Kun Mi and Jia Cheng and Huifen Liu and Cuirong Gu and Lingxiao Huang and Jianming Huang},
  title = {{All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells}},
  booktitle = {Research Square},
  year = {2020},
  doi = {10.21203/rs.2.18130/v3},
}

Loading related content...

Figure